Pediatric Blood & Cancer · 2005 · 102 citations · 24 references
MedicineEndocrinologyPediatricsImmunopathologyPediatric EndocrinologyPediatric PathologyBone DisordersBone PathologyPediatric Bone DiseasePediatric Bone Pathology
BACKGROUND: Our goal was to examine the clinical course of patients with Langerhans cell histiocytosis (LCH), with a special emphasis on bone disease and to attempt to identify and examine the factors that may predict reactivation and overall prognosis. PROCEDURE: We conducted a retrospective chart review of 132 consecutive pediatric patients treated at Children's Hospital Los Angeles for LCH from 1984 to 2001. RESULTS: The risk for reactivation after initial management is significantly higher for patients with multiple bone and those with multiple organ involvement as compared with patients who had a single bone lesion (hazard ratios are 7.1 and 11.6). Patients younger than 1 year in the multiple organ group have an increased risk of death at 2 years when compared with the older patients in that group (hazard ration = 6.2, P = 0.022). Endocrine abnormalities were seen in 20% and 7.5% of patients with or without skull lesions respectively. CONCLUSIONS: Patients with LCH involving only the bones have a significantly better outcome than those with other organ involvement. Patients with multiple organ involvement who are less than 1 year of age are at high risk of death and should be approached more aggressively upfront.
24
Principles and Practice of Pediatric Oncology
R. J. Labotka · JAMA · 2002 · 1.1K citations
Medicine, Oncology, Pediatrics +12
Histiocytes and histiocytosis [see comments]